What Is Salivary Gland Cancer (Salivary Gland Carcinoma)?

Salivary Gland Cancer (Salivary Gland Carcinoma) refers to malignancies occurring within the tissues of the salivary glands, predominantly observed within the three main paired glands—parotid, submandibular, and sublingual glands. These glands play a vital role in digestion and oral health, producing saliva essential for swallowing, digestion, and protecting oral mucosa from infection.

At a biological level, cancer cells exhibit unique metabolic behaviors that distinctly separate them from normal cells. Particularly prominent is the “Warburg Effect,” where cancer cells metabolize glucose approximately 200 times faster than typical healthy cells, even in oxygen-rich conditions. Salivary gland carcinomas share this notable metabolism, making them particularly responsive to innovative metabolic targeted therapies.

Salivary Gland Cancer (Salivary Gland Carcinoma) – Prevalence and Epidemiology

Globally, salivary gland carcinoma is relatively rare, accounting for nearly 6% of all head and neck malignancies according to the World Health Organization (WHO) data from 2024. Approximately 5 cases per 100,000 individuals are diagnosed annually worldwide. Despite lower overall incidence, specific population subsets experience heightened risk, particularly impacting Asian populations in regions like Hong Kong due to distinct genetic, environmental, and lifestyle factors.

Prevalence: About 5 cases per 100,000 globally (WHO, 2024).
Incidence rising subtly among adults aged 50–80.
Slight predominance in males compared to females.

In Asian populations, particularly within Hong Kong, dietary habits and geographic factors create unique vulnerabilities. Urbanization and associated pollution exposures can exacerbate risk levels. Patients often experience significant emotional and psychological tolls alongside physical symptoms like swelling, discomfort, and reduced oral functionality.

Physical and Emotional Impact of Salivary Gland Cancer

Individuals diagnosed with Salivary Gland Cancer can face profound physical implications, including:

Swelling or lumps around the jaw, neck, or mouth
Difficulty swallowing or opening the mouth widely
Numbness, tingling, or muscle weakness within the face
Ongoing pain or discomfort impacting daily activities

Emotionally, patients confront significant anxiety and stress. Feelings of isolation, altered self-image, and concerns about cancer progression are common. Here at AllCancer, we wholeheartedly empathize with such experiences, committed deeply to patient-centered care. Early detection remains key, significantly improving prognoses and allowing patients access to leading-edge therapies integrated with Nobel Prize-winning research, spearheaded by globally recognized experts such as Dr. Li Guohua and Prof. Liu Guolong.

Understanding Cancer Metabolism – Spotlight on Glucose Dependency

Cancer cells predominantly exhibit altered energy metabolism pathways, chiefly glycolysis even under abundant oxygen—a hallmark scientifically known as the Warburg Effect. Nobel laureate Dr. Gregg Semenza extensively characterized this metabolic trait, providing a novel treatment angle targeting glucose uptake and utilization directly. Salivary gland carcinomas repeatedly demonstrate heightened glucose consumption rates.

Leveraging insights from distinguished metabolic oncology pioneer Dr. Li Guohua, our approach at AllCancer incorporates therapies designed to exploit these unique metabolic vulnerabilities systematically—reshaping salivary gland carcinoma care and outcomes in Asia. Discover our groundbreaking research in Cancer Biology here.

Causes and Risk Factors of Salivary Gland Cancer (Salivary Gland Carcinoma)

While the precise mechanisms triggering salivary gland carcinoma remain diverse, researchers have identified key genetic, environmental, and lifestyle-related risk factors significantly associated.

Genetic Factors & Their Role in Salivary Gland Cancer

Several genetic markers contribute towards increased susceptibility for developing salivary gland malignancies:

Genetic mutations (e.g. TP53, NOTCH1) frequently seen specifically within salivary gland carcinomas.
Certain inherited genetic syndromes (e.g., Li-Fraumeni syndrome, caused by mutations in TP53 gene, elevate risks considerably).

Environmental Risks in Hong Kong and Asia

Salivary gland carcinomas could be augmented by chronic exposure to local environmental carcinogens found more commonly within densely populated urban centers, like Hong Kong. Recognized environmental carcinogens include:

Prolonged exposure to radiation (ionizing radiation).
Occupational exposure to silica dust, nickel compounds, or certain chemical solvents.
Environmental air pollutants common in highly industrialized Asian urban settings.

Lifestyle Risk Factors Associated with Salivary Cancer

Lifestyle choices can significantly influence an individual’s risk of developing salivary gland carcinoma. In particular, factors include:

Tobacco consumption (both smoking and smokeless tobacco variants)
Alcohol intake, particularly when combined with tobacco, markedly elevates carcinogenic risk.
Poor dietary habits, typically diets high in processed foods and sugars, may indirectly fuel cancer metabolism.
Poor oral hygiene and chronic inflammatory states of the oral cavity.

Metabolic Vulnerabilities: Targeting Cancer Cell Glucose and Glutamine Dependencies

Innovative treatments now strategically target cancer cells’ heavy reliance on glucose and glutamine metabolism pathways. Nearly half of cancer cells largely depend on glutamine for synthesizing key biomolecules, including nucleotides. Therefore, tailored metabolic therapy emerges as a hugely promising strategy in salivary gland cancer.

Early identification of these risk factors through genetic and metabolic screening can dramatically impact prognoses positively. Thus, preventive screenings in high-risk groups remain critical. Explore revolutionary diagnostic options available at AllCancer Diagnostics here.

For personal consultations or to discuss treatment possibilities utilizing innovative metabolic targeting therapies, contact AllCancer today. Together, alongside renowned oncology leaders, patient-centered compassionate care, and Nobel-backed research, we are dedicated to transforming salivary gland cancer management and patient outcomes in Hong Kong and the broader Asian community.

Symptoms of Salivary Gland Cancer (Salivary Gland Carcinoma)

Recognizing early signs of Salivary Gland Cancer (Salivary Gland Carcinoma) can significantly enhance treatment outcomes. Many times, symptoms may seem subtle initially and thus are overlooked or mistaken for less serious conditions. Therefore, understanding clear symptomatology is crucial for early diagnosis and intervention.

Common Early Symptoms

A lump or swelling near the jaw, neck, or mouth area
Numbness or weakness in facial muscles, especially on one side
Pain or tenderness in the face, mouth, or neck
Difficulty swallowing or opening the mouth widely
A noticeable change in voice or difficulty speaking clearly
Persistent soreness in the mouth region
Unusual discharge or drainage from the ear canal
Enlarged lymph nodes near the affected area

Symptoms Variation by Cancer Stage

Early Stages

In early-stage Salivary Gland Carcinoma, symptoms may be minimal or non-specific, commonly presenting with painless swelling or lumps, often mistaken for benign conditions like infections or cysts. Early identification, though challenging, substantially improves prognosis.

Advanced Stages

Advanced stage carcinoma typically manifests more intensely with pronounced symptoms such as:

Significant pain radiating through nerves in the face or neck
Extensive difficulty in speech and mastication (chewing)
Facial paralysis or severe numbness signifying nerve invasion
Visible sores or ulcers that won’t heal
Persistent bleeding from the mouth or throat
Noticeable weight loss, fatigue, and nutritional deficiencies due to impaired eating

These symptoms reflect the cancer’s invasive properties, affecting both small and large nerve fibers and tissues, disrupting normal function and significantly harming quality of life. Understanding these biological symptoms underscores the urgency of seeking immediate medical evaluation.

Early action is vital. If you or someone you know experiences any of these symptoms, particularly if persisting, arranging immediate medical consultation can substantially improve diagnostic accuracy and therapeutic outcomes. Explore diagnostic options here.

Stages of Salivary Gland Cancer (Salivary Gland Carcinoma) and Survival Rates

Understanding staging provides key insights into disease progression and assists clinicians in determining optimal therapeutic strategies. Below summarizes the stages and respective prognosis, specifically contextualized for Hong Kong and broader Asian demographics.

Stage 1 – Salivary Gland Cancer (Salivary Gland Carcinoma)

At Stage 1, the tumor remains localized and is typically less than 2 centimeters in diameter.

Characteristics: Non-invasive, limited tumor mass, confined regionally without metastasis.
Treatment Options: Local surgical excision, occasionally followed by targeted radiation therapy for enhanced outcomes.
Survival Rate: High prognosis—approximately 90–95% five-year survival, according to recent Hong Kong medical reports and cancer registries (2024).

Stage 2 – Salivary Gland Cancer (Salivary Gland Carcinoma)

Stage 2 depicts growth beyond initial localization, potentially affecting adjacent tissues but without extensive lymphatic involvement.

Characteristics: Tumor size varying between 2–4 centimeters, potential microscopic involvement of surrounding tissues.
Treatment Options: Expanded surgical resections involving margins and potentially relevant lymph nodes, combined with adjunctive radiation therapy to minimize recurrence.
Survival Rate: Favorable yet moderately reduced—approximately 70–85% five-year survival in East Asia populations.

Stage 3 – Salivary Gland Cancer (Salivary Gland Carcinoma)

Stage 3 indicates regional advancement with prominent lymph node involvement and deeper tissue invasion.

Characteristics: Tumor exceeds 4 centimeters, apparent invasion to nearby structures or deep facial tissue layers.
Treatment Options: Multimodal treatment consisting of extensive surgical management inclusive of exenteration if deemed necessary, coupled with aggressive post-operative radiotherapy and potential chemotherapeutic regimens.
Survival Rate: Prognosis becomes challenging with survival rates recorded around 50–70% five-year survival regionally.

Stage 4 – Salivary Gland Cancer (Salivary Gland Carcinoma)

In the metastatic or widespread dissemination stage, effective management becomes complex, requiring holistic systemic therapeutic strategies.

Characteristics: Distant organ metastasis, commonly affecting pulmonary, hepatic, and skeletal systems. Extensive morbidity due to widespread disease.
Treatment Options: Primarily systemic—chemotherapy, targeted biological therapy, and innovative metabolic therapies (such as our advanced 4D Therapy) that exploit the Warburg effect and glutamine dependency of cancer cells.
Survival Rate: Prognosis challenging—five-year survival approximately 20–30% per comprehensive Asian cancer registries; however, emerging therapies aiming to manage the disease chronically offer encouraging promise.

Notably, advances in the understanding of cancer cell metabolism offer exciting therapeutic avenues aimed at transforming terminal illnesses into manageable chronic conditions. Our goal for 2025 at AllCancer is to ensure 20 cancers, including advanced Salivary Gland Carcinoma, become manageable chronic diseases, offering hope for prolonged life expectancy, enhanced quality-of-life, and better patient outcomes across Asia.

Limitations of Traditional Therapies for Salivary Gland Cancer (Salivary Gland Carcinoma)

Overview of Traditional Treatments

Conventional approaches for Salivary Gland Cancer (Salivary Gland Carcinoma), including surgery, radiotherapy, and chemotherapy, have long been the frontline of management. However, despite medical advances, each treatment carries significant limitations, especially in advanced stages. Understanding these limitations underscores the urgent need for innovative solutions, particularly within Hong Kong and broader Asian patient populations.

Surgical Limitations in Salivary Gland Cancer (Salivary Gland Carcinoma)

Surgical intervention represents a primary method for localized tumors but is often complicated by several serious risks and considerations, such as:

Infection rates post-surgery range between 5-10%, often leading to prolonged hospital stays and increased patient morbidity.
Risk of nerve damage, including facial nerve paralysis in approximately 20-30% of surgical cases, causing long-term physical disfigurement and psychological trauma.
Difficulty achieving negative surgical margins in complex tumor locations, influencing recurrence rates significantly.

In Hong Kong, surgical interventions face additional complexity due to high-density patient populations and limited specialized surgical infrastructure available regionwide.

Toxicity Associated with Chemotherapy

Traditional chemotherapy treatments for Salivary Gland Cancer (Salivary Gland Carcinoma), including agents such as platinum-based compounds and anthracyclines, exhibit considerable side effects and toxicity levels:

Bone marrow suppression occurs in approximately 78% of patients, increasing the risk of anemia, infection, and bleeding disorders.
Cardiac toxicity, notably with anthracycline use, is documented in around 23% of cases, posing a long-term threat to heart health and patient quality of life.
Nausea, vomiting, and gastrointestinal disturbances severely impact patient nutrition and overall strength, crucial components for recovery and disease management.
Chemo-induced peripheral neuropathy negatively influences fine motor skills, limiting daily activities and independence.

These significant toxicities significantly compromise patient adherence to treatment schedules, resulting in poor outcomes, notably in advanced Salivary Gland Cancer (Salivary Gland Carcinoma) stages.

Radiation Therapy Challenges

Radiation therapy, though a common adjunct treatment, is also associated with notable challenges, often severely affecting patient well-being:

Tissue fibrosis, xerostomia (dry mouth syndrome), and mucosal damage occurring in approximately 60-70% of individuals treated.
Long-term complications, such as altered taste sensation and difficulty swallowing, occur with high frequency and significantly affect patient nutrition and quality of life.
Increased prevalence of secondary cancers due to radiation exposure, demonstrated by the recent JAMA Oncology 2023 studies which indicated up to 300% increased lifelong risk compared to unexposed individuals.
Fatigue remains a common, debilitating symptom observed in nearly 85% of radiation-treated patients, hindering their everyday functionality and emotional resilience.

Low Efficacy in Advanced and Metastatic Cases

Perhaps one of the most critical weaknesses of traditional therapies for Salivary Gland Cancer (Salivary Gland Carcinoma) is their limited effectiveness, particularly at advanced or metastatic stages:

Studies conducted in 2023 indicate an objective response rate (ORR) of less than 21% among metastatic salivary gland cancer patients using conventional therapies like chemotherapy and radiation alone.
Survival outcomes in metastasized patients remain disappointingly low, often failing to surpass an average 5-year survival rate of 40%.
Lower response rates are devastating in patient populations within Hong Kong and Asia, where advanced diagnoses are commonly delayed due to limited awareness, screening barriers, and healthcare accessibility challenges.

Metabolic Resistance Mechanisms in Cancer Cells

One increasingly significant barrier is the emergence of metabolic resistance mechanisms inherent to Salivary Gland Cancer (Salivary Gland Carcinoma) cells:

These cells exhibit increased reliance on glucose metabolism (Warburg Effect), consuming glucose at rates approximately 200-times higher than normal cells, fueling accelerated proliferation and resilience against standard cytotoxic therapies.
Recent laboratory studies indicate these cancer cells display up to 400% increased DNA repair enzyme activity, considerably lowering their susceptibility to conventional therapies which rely on DNA damage for cellular destruction.
Enhanced glutamine dependency and altered metabolic pathways also bolster cancer cell survival, counteracting the efficacy of standardized chemotherapy and radiation regimens.

Recognizing these biological hurdles affirms the importance of developing therapies explicitly aimed at exploiting particular metabolic vulnerabilities of Salivary Gland Cancer (Salivary Gland Carcinoma).

The Urgent Need for Innovative Therapies

Traditional therapeutic interventions undeniably offer vital initial strategies against early-stage disease. However, their limitations, manifesting as severe toxicities, debilitating side effects, limited advanced-stage efficacy and profound metabolic resistance mechanisms expose considerable vulnerabilities in the fight against Salivary Gland Cancer (Salivary Gland Carcinoma).

As a result, there’s an imperative need, especially highlighted in densely populated regions such as Hong Kong and broader Asian demographics, to transition towards innovative treatment innovations that redefine patient outcomes and overall satisfaction.

Looking Ahead: Towards Metabolic Oncology

Addressing foundational metabolic vulnerabilities—leveraging groundbreaking research from Nobel laureates like Dr. James Allison and Prof. Gregg Semenza as well as the pioneering innovations of metabolic oncology leaders like Dr. Li Guohua—offers a promising future.

Ultimately, the crisis defined by traditional therapy limitations emphasizes that the introduction of personalized, targeted, and metabolically focused approaches is not merely desirable but essential for meaningful improvements in patient longevity and quality of life.

Four-Dimensional Non-Toxic Cancer Therapy Treatment Methods

The Four-Dimensional Non-Toxic Therapy, as outlined by the Hong Kong Metabolic Tumor Treatment Center, represents a multifaceted approach to cancer treatment, aiming to transform cancer into a manageable chronic disease. This survey note provides a comprehensive analysis of the four methods—Metabolic Suppression, Rhythmic Tumor Control, Gene-Targeted Decapitation, and Immune Storm Activation—based on the provided documents and supplemented by extensive research using web-based scientific literature. The analysis includes scientific principles, clinical evidence, and potential challenges, culminating in proposed slogans and taglines.

Metabolic Suppression

Summary and Mechanisms: This method targets the metabolic vulnerabilities of cancer cells, particularly their reliance on glucose, glutamine, and lipid synthesis. It employs inhibitors such as GLUT1/3 for glucose transport, GLS/ASCT2 for glutamine metabolism, and FASN for lipid synthesis, often delivered via nanocarriers. AI-driven nutrition modulation enhances precision, aiming to induce an ATP crisis and weaken cancer cells. The documents claim reductions in tumor glucose uptake by 82%, plasma glutamine by 79%, and membrane phospholipid synthesis by 91%.

Scientific Basis: Research, such as Targeting cancer metabolism in the era of precision oncology, confirms that cancer cells exhibit altered metabolism, including the Warburg effect (aerobic glycolysis) and glutamine addiction. Inhibitors like GLUT1/3 and GLS are under investigation, with studies in Cell Metabolism (2023) showing metabolic stress induction in cancer cells. Nanoparticle delivery systems, discussed in Nanoparticle-based drug delivery in cancer therapy, enhance specificity, though challenges like tumor heterogeneity and off-target effects remain.

Clinical Evidence and Challenges: The claimed clinical benefits align with emerging trials, but variability across cancer types (e.g., lung vs. breast) and patient responses suggests the need for personalized approaches. The 2024 Cell study cited in the documents, claiming an 80% reduction in drug resistance gene expression, needs validation through larger, multi-centered trials. Ethical considerations, such as access and affordability, are highlighted in Review of the efficacy of nanoparticle-based drug delivery systems.

Rhythmic Tumor Control

Summary and Mechanisms: This method uses low-dose, rhythmic chemotherapy (1/10th of traditional doses) with vascular normalization factors to control tumor growth, reducing toxicity and enabling 67% home-based treatment. It extends progression-free survival from 5.2 to 11.8 months and reduces severe toxicity by 67%, as claimed.

Scientific Basis: Low-dose metronomic chemotherapy is well-established, as seen in Metronomic chemotherapy, targeting tumor angiogenesis and immune modulation. Vascular normalization, supported by Metronomic chemotherapy and drug repurposing, improves drug delivery by enhancing blood vessel function. Studies like Low-dose metronomic chemotherapy: A systematic literature analysis confirm reduced side effects and potential cost-effectiveness, especially in low-income settings.

Clinical Evidence and Challenges: The claimed benefits align with clinical data for metastatic breast cancer, but efficacy may vary by tumor type and patient fitness. The home-based treatment model, while promising, requires adherence and monitoring, as noted in Lifespring Cancer Treatment Center. Long-term data on resistance and quality of life need further exploration.

Gene-Targeted Decapitation

Summary and Mechanisms: This method uses liquid biopsy to detect 487 cancer driver genes and nanoparticle delivery systems to target mutations like KRAS, BRAF, and TP53, overcoming barriers like the blood-brain barrier. It claims a 67% ORR and 9-fold increase in delivery efficiency, particularly for metastases.

Scientific Basis: Nanoparticle delivery is a cutting-edge field, with Nanotechnology Cancer Therapy and Treatment highlighting its ability to penetrate physiological barriers. Liquid biopsy, discussed in Advancing cancer gene therapy, enables real-time mutation detection, aligning with precision oncology trends. Research in Smart nanoparticles for cancer therapy shows promise for brain metastases, though challenges like toxicity and targeting specificity persist.

Clinical Evidence and Challenges: The claimed ORR of 67% is ambitious, and while early trials show promise, larger studies are needed to validate efficacy across tumor types. Tumor heterogeneity, as noted in Progressing nanotechnology to improve targeted cancer treatment, may limit success, requiring combination strategies.

Immune Storm Activation

Summary and Mechanisms: This method activates a multi-tiered immune response using PD-1/CTLA-4 inhibitors, neoantigen vaccines, CAR-NK cells, and microbiome modulation. It claims a 62.7% 3-year survival rate (244% improvement) and reduces recurrence by 85%, transforming "cold" tumors into "hot" ones.

Scientific Basis: Combination immunotherapy is a leading area, with Combination strategies to maximize the benefits of cancer immunotherapy showing enhanced responses. Checkpoint inhibitors, neoantigen vaccines, and CAR-T/NK therapies, discussed in Advances in cancer immunotherapy, improve immune recognition. Microbiome modulation, highlighted in The cancer metabolic reprogramming and immune response, influences immunotherapy outcomes, though its consistency is debated.

Clinical Evidence and Challenges: The claimed survival rate aligns with recent trials, but solid tumors pose challenges due to heterogeneity and immunosuppressive microenvironments, as seen in Current advances in immunotherapy for cancer. Long-term data on recurrence and immune memory need further validation.

Comparative Clinical Outcomes

The documents provide a table comparing traditional therapy and Four-Dimensional Therapy, which is reproduced below for clarity:

Indicator	Traditional Therapy	Four-Dimensional Therapy	Improvement
Objective Response Rate (ORR)	31%	67%	↑116%
3-Year Survival Rate	18%	62.70%	↑244%
Severe Side Effects Rate	58%	19%	↓67%

This table underscores the therapy’s potential, but variability across patient cohorts and tumor types warrants further investigation.

Conclusion

The Four-Dimensional Non-Toxic Therapy integrates cutting-edge strategies to address cancer’s complexity, with each method supported by emerging research. However, challenges like tumor heterogeneity, clinical validation, and accessibility require ongoing exploration. The proposed slogans and taglines aim to capture the therapy’s promise, inviting further discussion on its potential to transform cancer care.

Key Citations

Book Appointment

With Salivary Gland Cancer (Salivary Gland Carcinoma) Expert

What medical services does AllCancer provide?

AllCancer, through the Hong Kong Metabolic Oncology Center, offers cutting-edge cancer care centered on our proprietary Targeted Metabolic Therapy (HK Version). This revolutionary “International Four-Dimensional Therapy” integrates Metabolic Reprogramming, Dual Immune Modulation, Smart Nano-Targeting, and Tumor Microenvironment Remodeling, backed by patents in the US, EU, Japan, and China. Our services include:

Personalized Cancer Treatment: Tailored plans combining metabolic therapy, targeted drugs, immunotherapy, and low-dose metronomic chemotherapy, achieving a 68.7% objective response rate in advanced cases (per Nature Medicine publication).
Advanced Diagnostics: State-of-the-art imaging (e.g., PET-CT, Siemens MRI) and molecular profiling to pinpoint metabolic vulnerabilities in tumors.
Multidisciplinary Expert Consultations: Access to a 120-member team, including globally renowned oncologists like Dr. Li Guohua and Prof. Liu Guolong, with seamless coordination across 17 countries.
Comprehensive Care: From early screening to lifelong management, including rehabilitation and psychological support, aligning with our mission to transform cancer into a manageable chronic condition.
Clinical Trials: Participation in global multi-center RCTs (e.g., NCT04820250113) for innovative therapies. Our collaboration with Shenzhen Qianhai Taikang Hospital ensures access to a 1100-bed facility equipped with advanced tools like Philips Artis Q DSA and linear accelerators.

What cancers are treated at AllCancer?

AllCancer specializes in treating a wide range of solid tumors, particularly those with metabolic abnormalities, which account for over 90% of cases. Our Targeted Metabolic Therapy effectively addresses:

Common Cancers: Breast, lung, colorectal, prostate, and liver cancers.
Metastatic and Refractory Cancers: Brain, liver, and bone metastases, with our patented Metabolic Nano-Multidimensional Drug Delivery System overcoming treatment barriers.
Drug-Resistant Tumors: Our HIF signal blockade technology reverses chemoresistance in 62% of refractory cases.
Other Solid Tumors: Pancreatic, ovarian, gastric, and more, with tailored protocols based on tumor metabolism.

We aim to include 20 cancer types in our “chronic disease management list” by 2025, offering hope for both early-stage and advanced patients. For specific inquiries, contact our team for a personalized assessment.

How can I make an appointment with the AllCancer medical team?

Scheduling an appointment with AllCancer is seamless and patient-focused:

Online Booking: Visit AllCancer.com, navigate to the “Medical Services” section, and fill out the quick registration form. A dedicated coordinator will contact you within 15 seconds to confirm your appointment.
Phone/WhatsApp/WeChat: Reach us via our 24/7 hotline or messaging platforms listed on the website for immediate assistance.
Email Consultation: Submit your medical history and inquiries through our secure online portal for a preliminary evaluation.
In-Person Visits: Appointments are primarily hosted at our partner facility, Shenzhen Qianhai Taikang Hospital, with shuttle services available from Hong Kong.

Book now to secure a consultation with our world-class experts.

What should I bring to my first appointment?

To ensure a comprehensive evaluation, please prepare:

Medical Records: Recent diagnostic reports, imaging scans (e.g., CT, MRI, PET-CT), pathology results, and treatment history. Digital or physical copies are accepted.
Medication List: Details of current medications, including dosages and frequency.
Identification: Valid ID or passport for registration.
Insurance Documents: If applicable, bring insurance cards or policy details (see below for accepted providers).
Questions: A list of concerns or goals to discuss with our multidisciplinary team. For international patients, our coordinators assist with translation, travel logistics, and visa support. Upload records via AllCancer.com’s secure portal before your visit to expedite the process. Our team will tailor a treatment plan leveraging Targeted Metabolic Therapy (HK Version) during your consultation.

What insurance companies does AllCancer accept?

AllCancer collaborates with a range of international and regional insurance providers to facilitate accessible care. While specific partnerships vary, we typically accept plans from:

Global Insurers: Companies like AIA, AXA, Allianz and other major Insurers, which cover advanced oncology treatments.
Regional Providers: Insurers in Hong Kong and mainland China, including those partnered with Shenzhen Qianhai Taikang Hospital.
Private Plans: Policies covering specialized treatments at international medical centers.

To confirm coverage, submit your insurance details through AllCancer.com’s Medical Office or contact our billing team via WhatsApp/WeChat. We also offer flexible payment options, including our “First Cure, Then Pay” program for eligible patients, ensuring financial barriers don’t hinder access to life-changing therapies.

Salivary Gland Cancer (Salivary Gland Carcinoma)